FTC Gives Green Light To ANI-Novitium Acquisition Conditions
Follows Public Comment Period; ANI Announced Completion In November
ANI is now firmly in the clear for its $210m acquisition of Novitium, following FTC approval of an order requiring divestiture of rights and assets to two generic products. The US-based firm is on an upward trajectory following its recent approval for Cortrophin Gel.
You may also be interested in...
Licensing deals and partnerships carried the day during another hectic J.P. Morgan Healthcare Conference. Pfizer racked up its third deal of the week in a cancer collaboration with Dren Bio.
ANI Pharmaceuticals has struck a deal worth up to $210m to acquire niche generics specialist Novitium Pharma, a move that the firm says will bring it a healthy pipeline of ANDAs and 505(b)(2) products as well as enhancing its CDMO business.
Apotex has moved first on Allergan’s Combigan, introducing a US authorized generic as the clock ticks on the originator’s IP. Sandoz is among ANDA sponsors seemingly waiting for patent protection to lapse.